Peripheral blood mononuclear cells (PBMC) were collected after the administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and used as the sole source of hematopoietic stem cells after myeloablative therapy with busulfan (Bu) and cyclophosphamide (Cy). These studies were performed in 12 patients with malignancies (4 nomHodgkin's lymphoma, 5 breast cancer, 1 testicular carcinoma, 1 Wilm's tumor, and 1 undifferentiated carcinoma) who had bone or bone marrow disease or had low marrow cellularity. rhG-CSF (1 6 pg/kg/d) was administered for 5 to 7 days by subcutaneous injection and PBMC were collected for 2 to 5 days beginning on day 4 after initiation of rhG-CSF, using continuous-flow bloodcell separators that processed 10 to 1 2 L of whole blood. From a median of three collections, a mean of 24.0 X 10' ( 2 10.5 SD) total nucleated cells/kg containing 12.6 X 1 O8 ( k 4.5 SD) mononuclear cells/kg, 7.3 X 1 O6 ( f 4.3 SD) CD34+ cells/kg and 20.5 X 1 O4 ( f 28.1 SD) granulocyte-macrophage colony-forming units (CFU-GM)/kg RYOPRESERVED autologous marrow is commonly C used to restore hematopoiesis after intensive marrow ablative therapy in patients with leukemia, lymphoma, and solid tumors.' In recent years, peripheral blood mononuclear cells (PBMC) have been used as a source of hematopoietic stem cells in patients with marrow disease or inadequate marrow f u n c t i~n .~,~ However, 6 to 8 collections by leukapheresis are required to harvest sufficient cells for consistent engraftment, the tempo of which has not been superior to that observed after marrow i n f~s i o n .~.~ Cytotoxic chemotherapy can be used to increase the concentration of granulocyte-macrophage colony-forming units (CFU-GM) in the PB.5-7 PBMC collected after chemotherapy can enhance hematopoietic recovery after myeloablative therapy when administered with or without Recombinant human (rh)GM-CSF has been used after the administration of high doses of cyclophosphamide or etoposide to further enhance collections of PB hematopoietic precur-were harvested and cryopreserved. After the administration of Bu 14 to 17 mg/kg and Cy 120 to 150 mg/kg, PBMC were thawed and infused. One patient received rhG-CSF after the infusion of PBMC and the remaining 11 patients did not receive postinfusion growth factors. Mean days to recovery of neutrophil levels of 0.1,0.5, and 1 .O X 1 09/L were 1 1.4 (range, 9 to 13). 12.7 (range, 10 to 15). and 13.6 (range, 1 1 to 16) and the mean day to platelet transfusion independence was 13.3 (range, 7 to 49). Time to recovery of neutrophils to 0.5 and 1 .O X 1 09/L and platelets to 20 X 1 09/L was more rapid than in historical patients treated with Bu and Cy who received marrow alone or marrow followed by the posttransplant administration of rh-G or GM-CSF. No graft failures have been observed with a follow-up of 4 to 12 months. These results indicate that PBMC collected after rhG-CSF lead to rapid hematopoietic recovery after myeloablative chemotherapy.
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SOTS.'','~ However, for some patients, especially those who have received previous intensive chemotherapy, little or no increase in the PB concentration of CFU-GM or CD34+ cells is observed after chemotherapy and rhGM-CSF administration."
In heavily pretreated patients with advanced malignancies, mononuclear cells collected after the administration of rhGM-CSF, but without prior chemotherapy, have been infused after myeloablative therapy with engraftment patterns similar to that observed with marrow infu~ion.'~,'~ In a group of patients with Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), and acute lymphoblastic leukemia who had received prior treatment, rhG-CSF has also been used without prior cytotoxic chemotherapy to mobilize and collect large numbers of PBMC that, when infused with marrow, result in rapid recovery of neutrophils and platelets after myeloablative therapy.I5 These studies suggested that rhG-CSF may mobilize large quantities of hematopoietic progenitor cells. This report describes the successful use of PBMC collected after the administration of rhG-CSF to repopulate the marrow in patients who had received myeloablative therapy with busulfan (Bu) and cyclophosphamide (Cy).
PATIENTS AND METHODS
Patients were referred to the Fred Hutchinson Cancer Research Center (FHCRC) for consideration of autologous marrow harvest and transplant. Patients were eligible for autologous transplant using PBMC if they had histologic evidence of marrow disease, a marrow cellularity of less than 60% of normal, or evidence of widespread metastatic bone disease by isotope Scan or magnetic resonance imaging (MRI). Patients with breast cancer were also eligible if histologic or immunocytochemistry (ICC) analysis of mamow showed tumor cells.'6 Three patients had autologous marrow harvested before the administration of rhG-CSF and collection of PBMC while 9 patients did not undergo marrow harvest. Informed consent was obtained using protocols and forms approved by the FHCRC Institutional Review Board. The characteristics of the I2 patients undergoing autologous transplantation with PBMC are shown in Table I . The reasons for entry on this protocol included 2 patients with low marrow cellularity (30% and 50% of normal), 2 patients with extensive skeletal disease by MRI but without histologic evidence of marrow disease, 4 patients with breast cancer who were ICC positive, and 4 patients who had tumor in the marrow (5% to 25%) by histologic examination. All but one patient had recurrent disease detected by scans or standard xrays.
rhG-CSF (Amgen, Thousand Oaks, CA) was administered by subcutaneous injection (16 pg/kg) daily for 5 to 7 days. This dose was chosen on the basis of studies showing a maximum PB progenitor concentration at a G-CSF dose of 10 to 30 pg/kg." Leukapheresis was initiated 18 to 24 hours after the third dose of rhG-CSF and doses 4 to 7 were administered after each apheresis procedure. Leukapheresis was performed with the use of automated continuousflow blood cell separators (Spectra, Cobe Laboratories, Engelwood, CO, CS-3o00, Fenwal Inc, Round Lake, IL). Anticoagulant, consisting of 2% trisodium citrate and heparin 20 U/ml in 0.9% sodium chloride, was infused at a ratio of 1 mL anticoagulant to 10 mL whole blood. Collection of the mononuclear cell interface was performed until I0 to 12 L of whole blood were processed. Collections were performed for 2 to 5 consecutive days. The leukapheresis product was cryopreserved in 10% dimethyl sulfoxide (DMSO) and 20% autologous plasma using a controlled-rate liquid nitrogen freezer and stored in the vapor phase of liquid nitrogen."
CFU-GM were measured by plating 1 X lo5 PBMC in a 1.25% methylcellulose solution containing 10% lymphocyte-conditioned media, 10% human plasma, 20% fetal calf serum (FCS), 9% Iscoves media, and 5 X 10 to 5 mol/L 2-mercaptoethanol. Colonies of greater than 50 cells were counted on an inverted microscope after 14 days.
The quantities of CD34+ cells in the mononuclear cell collection were determined. A 1-mL sample of the leukapheresis product or PB was hemolyzed with ammonium chloride hemolytic buffer and washed twice with phosphate buffered saline (PBS) containing 2% human AB serum, and aliquoted into tubes at I X IO6 cells per tube. Patients received Bu 14 to 17 mg/kg orally over 4 days in 16 divided doses and Cy 120 to 150 mg/kg intravenously (IV) over 2 to 3 days. One patient with testicular cancer received carboplatin 450 mg/m2/ d for 3 days in addition to Bu and Cy. PBMC were thawed and infused and the day of infusion was designated day 0. One patient received rhG-CSF 5 pg/kg on days 0 to I3 after PBMC infusion while 11 patients did not receive growth factors after PBMC were infused.
Supportive care included private rooms, RBC and platelet transfusions, and antibiotics as previously descrikd.' Daily complete blood counts were performed and marrow samples were obtained on day 21. Time to engraftment was assessed by determining the day after transplant on which patients achieved 0.1, 0.5, and 1.0 neutrophils X 109/L and 20 X IO9 platelets/L, independent oftransfusion support. Engraftment parameters were evaluated in two historical groups of patients who underwent autologous marrow transplantation between 1986 and 1992 and did not receive PBMC. The first group (group 1) consisted of 21 patients who were transplanted with autologous bone marrow alone after Bu 16 mg/kg and CY 120 mg/kg and no posttransplant growth factors. The second group (group 2) consisted of 10 patients who received Bu (14 to 16 mg/kg) and Cy (1 50 to 174 mg/kg) followed by posttransplant rhG-CSF (5 Wg/kg/d) or rhGM-CSF (250 pg/m2/d). Two patients in group I and three in group 2 received marrow that was treated with four different anti-B-cell MoAbs and complement (Table All but one patient had received prior combination chemotherapy. There were no differences between groups in the median number of cycles of chemotherapy, number of patients who received salvage chemotherapy, or number of patients who received prior treatment with busulfan, bis-chloroethyl-nitrosourea (BCNU), procarbazine, or nitrogen mustard (Table   The probabilities of achieving 0.1 /0.5/ 1 . O neutrophils X I 09/L and 20 platelets X 109/L were determined using the product-limit estimates of Kaplan and Meier." The times to achieve these levels were compared among groups using the generalized Wilcoxon log-rank test. Statistical comparisons were made between the mean number of units of blood product transfusions received by each group using the Student's t-test.
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RESULTS
rhG-CSF was well tolerated with complaints of bone aches in four patients and no patient had to discontinue rhG-CSF because of side effects. 
6
Days of G-CSF The administration of rhG-CSF resulted in an increase in the peripheral WRC count from a mean of4. (Table 3) .
Myeloablative therapy was initiated a median of 9 days (range 8 to 98) after completing leukapheresis. Doses ofchemotherapy administered are shown in Table I . After the infusion of mononuclear cells, the median number of days with a neutrophil level of <O.l X IO"/L was 7 (range 5 to IO). Ten 
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For personal use only. on October 23, 2017. by guest www.bloodjournal.org From of 12 patients achieved a platelet count of 20 X 109/L within 14 days of PB mononuclear cell infusion (Table 4) . One patient (who received carboplatin) died on day 16 of acute respiratory distress syndrome without recovery of platelet counts. One patient achieved a platelet count of >20 X lo9/ L independent of transfusion support on day 49. The three patients who had previous autologous marrow stored did not require infusion of the backup marrow. When compared with two historical groups of patients who underwent autologous marrow transplant, the recovery of neutrophils to 0.5 and 1.0 X 109/L and of platelets to 20 X 109/L was significantly faster in the group receiving PB mononuclear cells (Table 5 ).
The number of RBC and platelet transfusions required was significantly less in patients receiving PB than in either historical control group.
In general, the quantity of CFU-GM X 104/kg and CD34+ cells X 106/kg were correlated with each other with an r value equal to .732 (data not shown). Unique patient number (UPN) 6,860, who died on day 16 without recovery of platelets, had the lowest quantity of CD34' cells infused (0.5 X 106/kg) with a relatively low quantity of CFU-GM infused (6.9 X 106/kg) ( Table 3) . UPN 691 1, who did not recover platelets until day 49, had the second lowest quantity of CD34' cells (1.6 X 106/kg) and the lowest quantity of CFU-GM infused (2.4 X 104/kg) of the entire group.
Ten of the 12 patients in this study survive with normal PB counts, independent of transfusions a median of 5 months (range 4 to 12) after transplant.
DISCUSSION
There has been interest in the use of PB hematopoietic precursors as an alternative to marrow for autologous transplantation. Transplantation of PB cells avoids the risks of marrow aspiration, may result in faster engraftment, and may allow autologous transplants in patients with inadequate marrow cellularity or marrow contaminated with tumor.22 However, in the steady state very few hematopoietic progenitors are found in the An average of 6 to 8 leukapheresis procedures are required to collect sufficient cells for engraftment and the tempo of engraftment has not been superior to m a r r o~.~?~ PBMC collected in the steady state do not accelerate the recovery of PB counts when infused with
The concentration of committed hematopoietic progenitors in PB can be increased 1 0-fold by giving cytotoxic therapy to previously untreated patients and this increase can be am- For personal use only. on October 23, 2017. by guest www.bloodjournal.org From plified another IO-to 1 00-fold by administering rhG-CSF or rhGM-CSF after chemotherapy.'',25 We and others have observed that, in heavily pretreated patients, the use of chemotherapy plus rhGM-CSF has high patient to patient variability with some patients having little or no increase in CFU-GM or CD34' cells in blood.'* rhG-CSF or rhGM-CSF will increase the quantity ofCFU-GM and CD34' cells in the blood without the administration of ~hemotherapy.'~.'~ The infusion of marrow and mononuclear cells collected after rhG-CSF or rhGM-CSF, followed by the posttransplant administration of rhG-CSF or rhGM-CSF enhances the recovery of platelets and neutrophils when compared with marrow with or without the administration of posttransplant growth f a c t~r s . '~.~~ Initial experience using rhGM-CSF mobilized PBMC alone for autologous transplantation indicated that granulocyte and platelet recovery was similar to that observed after marrow infu~ion.'~.'~ In a group of 16 patients with breast cancer who received adriamycin, 5-fluorouracil, and cyclophosphamide followed by rhGM-CSF to mobilize stem cells, there was an apparent acceleration in the recovery of blood counts when these peripheral blood stem cells (PBSC) were infused after high-dose ~hemotherapy.'~ However, 3 of the 16 patients in that study required infusion of the backup marrow because of poor platelet engraftment. The doses of rhGM-CSF administered to these patients and the WBC counts they achieved before collection were relatively modest.
In this report a 5 to 7 day course of rhG-CSF, 16 pg/kg/ d, was evaluated in a group of patients considered to be poor candidates for autologous marrow harvest. The administration of rhG-CSF resulted in substantial increases in WBC counts that were predominantly mature and immature granulocytes but included an increase in the quantity of mononuclear cells, CD34' cells, and CFU-GM. Infusion of PB cells collected after the administration of rhG-CSF resulted in rapid recovery of neutrophils and platelets in patients conditioned with Bu and Cy. The recovery was more rapid after the infusion of mononuclear cells collected after rhG-CSF than was observed in patients who received marrow with or without posttransplant rhG-CSF or rhGM-CSF in our study.
Although more than I week elapsed between the administration of rhG-CSF and the start of the conditioning regimen, it is impossible to rule out a protective effect of growth factor administration. Because this was not a randomized study and the patient groups are not identical, these results must be interpreted with caution. There were more patients with HD and multiple myeloma in the two control groups. In patients with a diagnosis of HD and perhaps with multiple myeloma, prior treatment with alkylating agents such as carmustine, procarbazine, and melphalan before marrow storage could have damaged marrow stem cells in these patients and in part could account for slower engraftment." However, recipients of PBMC in our study included 4 patients with histologically proven marrow disease and 2 patients with hypocellular marrows, making them less likely to have adequate marrow function.
In our study only 2 of 12 patients failed to achieve platelets of 20 X 109/L within 14 days posttransplant (UPN 6860 and 691 I). It is of interest that both patients received the lowest numbers of CD34+ cells and 1 of the 2 received the lowest quantity of CFU-GM infused.
In a recent report, the infusion of PB cells collected after rhG-CSF and administered with marrow followed by the infusion of rhG-CSF resulted in very rapid recovery of granulocytes and platelets; possibly more rapid than observed with mononuclear cells alone in the current study.I5 rhG-CSF or rhGM-CSF administered after the infusion of rhG-CSF mobilized PBMC could result in a further acceleration of recovery of neutrophils and platelets.
A major concern with the use of PB cells is that early engraftment will be achieved by the infusion of committed hematopoietic precursors but that permanent engraftment will be limited by a lack of more primitive hematopoietic precursors. The follow-up of patients enrolled in this study is short and the long-term durability of engraftment is unknown and must await a longer follow-up. However, it will be impossible to measure the contribution of autologous PBMC to long-term engraftment without genetic markers. If repopulation of marrow ultimately occurs from residual endogenous stem cells, the infusion of committed precursors would still be useful in overcoming the short-term effects of myeloablative therapy.
This study did not address the issue of potential contamination of PB by circulating tumor cells. Such contamination could occur naturally or may be increased if tumor cells are mobilized by rhG-CSF. Although relatively few studies have addressed the issue of residual disease in PB, two reports indicate fewer malignant cells in PB in the steady state as compared with
The potential for circulating tumor cells to cause relapse will need to be addressed in future studies using PB cells for engraftment in patients where marrow transplantation is an option.
The results of this study indicate that a short course of high-dose rhG-CSF can result in the mobilization of significant numbers of hematopoietic precursor cells that can be used to ensure hematopoietic recovery after marrow ablation. The study also suggests that the use of PBMC collected after the administration of rhG-CSF results in significantly faster recovery of PB counts than marrow or marrow followed by the administration of rhG-CSF or rhGM-CSF. Prospective controlled trials and a longer follow-up will be needed to confirm these observations.
